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psychostimulants, and received signiﬁcantly higher doses
of psychostimulants, suggesting disparities in AD/HD
treatment between boys and girls that may affect quality
of care.
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Opolka J1, Rascati K1, Brown C1, Gibson P2
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OBJECTIVES: Clinicians treating schizophrenia face
increasingly diverse populations, with different ethnic
groups having different medication adherence patterns.
The Texas Medicaid population with schizophrenia
includes large numbers of patients from several ethnic
groups, having broad use of the prevalent antipsychotic
medications within each ethnic group. The purpose of this
study was to assess the association between ethnicity and
adherence among Texas Medicaid clients with schizo-
phrenia, and to assess whether adherence within or across
ethnic groups differed depending on which antipsychotic
was used, after controlling for other factors. METHODS:
Texas Medicaid claims were retrieved for persons, age 21
to 65, diagnosed with schizophrenia or schizoaffective
disorder, initiating treatment with olanzapine (N = 1875),
risperidone (N = 982), or haloperidol (N = 726) between
1/1997 and 8/1998. For each of the three pairings of these
medications, the association between ethnicity (African
American, Mexican American, or Caucasian) or medica-
tion and days use of the medication in the year following
initiation was assessed using multivariate linear regres-
sion. Covariates included other patient demographics,
region, comorbid health conditions, and prior medication
and heath care resource use. RESULTS: Overall mean
adherence was 177 of 365 days (48.5%). African 
Americans and Mexican Americans were signiﬁcantly less
adherent than Caucasians in the haloperidol versus 
olanzapine and risperidone versus olanzapine compar-
isons (p < 0.05 for each comparison). For patients of all
ethnicities, olanzapine was associated with 19 more
adherent days than risperidone and 56 more adherent
days than haloperidol (p < 0.001 for each pairwise com-
parison). CONCLUSIONS: When other factors were 
controlled for 1) ethnicity was a signiﬁcant predictor of
adherence following initiation on an antipsychotic 
medication and 2) patients of all ethnicities were most
adherent when taking olanzapine, less adherent when
taking risperidone, and least adherent when taking
haloperidol.
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OBJECTIVES: The Quality of life in Depression Scale
(QLDS) is the most widely used measure of quality of 
life (QoL) in clinical trials and studies of depression. 
The instrument has been validated in 18 languages. The
instrument, which adopts the needs model, is highly 
sensitive to changes in QoL and is well accepted by
respondents. Since its development new statistical models
have been introduced into instrument development. The
present study was designed to adapt the QLDS using item
response theory in order to improve its measurement
properties further. METHODS: Existing datasets were
subjected to Rasch analysis to identify misﬁtting items
and to look for gaps in the range of measurement. As
weaknesses were identiﬁed at the extremes (very good 
or very poor QoL) additional interviews were conducted
with patients scoring either high or low on the QLDS and
new qualitative analyses were made of the 40 original
interview transcripts. Potential new items were added to
the QLDS and poorly performing ones removed. This
version was administered to samples of depressed patients
in the UK, US, France and Germany. The data were again
subjected to Rasch analysis and a ﬁnal version identiﬁed.
Its psychometric properties were then assessed in a second
postal survey. RESULTS: A 30-item version was identi-
ﬁed with little item misﬁt or differential item functioning
in the different countries. This version had excellent 
psychometric properties including reproducibility and
construct validity. The main gain was an increase in the
measurement range from 2.5 to 4.3 logits, an increase of
72%. CONCLUSIONS: The measurement properties of
the QLDS have been improved, ensuring it provides valid
scores on a unidimensional QoL scale. The increased
measurement range makes the instrument more suitable
for use across the full range of depression severity and
hence more valid for use in antidepressant maintenance
studies.
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OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and cost associated
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with Attention Deﬁcit/Hyperactivity Disorder (ADHD) in
children. The objective of this abstract is to present the
results on the burden (intangible costs) ADHD imposes
on the individual, the family and society in terms of
symptom persistence, violence, antisocial behaviour,
crime, substance misuse, social adjustment, academic 
performance. METHODS: The international literature
search was complemented by country-speciﬁc literature
searches in France, Germany, Italy, Netherlands, Spain
and the UK. In each country a clinical expert was inter-
viewed and reviewed the country-speciﬁc information.
RESULTS: Sources reporting the intangible conse-
quences/costs of ADHD were limited with literature from
the UK, France, Spain and Sweden. Literature suggests
that pervasively hyperactive symptoms in childhood is a
risk factor for poor outcomes in later development with
ADHD symptoms persisting into school leaving age and
nearly half of hyperactive children given a psychiatric
diagnosis. The literature review found reports indicating
that hyperactivity was a determinant of violence, aggres-
sion, deﬁant and disruptive behaviours, stealing, shoplift-
ing, joyriding, vandalism, offending and contact with the
police. Reports suggest a causal link between ADHD and
substance misuse but there is no consensus. Childhood
hyperactivity was reported to be a strong predictor of
relationship problems with links between hyperactivity
and moderate to severe problems in social functioning.
Reports from UK, France and Spain indicate that acade-
mic problems in school were more frequent in children
displaying hyperactive symptoms with language disor-
ders, reading, writing, cognitive and/or social develop-
ment difﬁculties. CONCLUSION: The consequences of
ADHD for the individual are potentially very severe and
we can infer this imposes a signiﬁcant burden upon the
family unit and society. ADHD symptoms can persist into
adolescence, and the hyperactive element of ADHD can
be predictive of violence, antisocial behaviour, crime,
poor social adjustment, substance abuse, and academic
problems.
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OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and cost associated
with Attention Deﬁcit/Hyperactivity Disorder (ADHD) in
children. The objective of this abstract is to present the
results on deﬁnition of the disorder, diagnosis, prevalence,
demographics, age of onset and treatment guidelines,
treatment in Europe. METHODS: The international 
literature search was complemented by country-speciﬁc 
literature searches in France, Germany, Italy, Nether-
lands, Spain and the UK. In each country a clinical expert
was interviewed and reviewed the country-speciﬁc infor-
mation. RESULTS: Across Europe, literature reﬂects 
the use of both the ICD-10 deﬁnition of Hyperkinetic 
Disorder (HD), and the DSM-IV deﬁnition of ADHD. 
In Italy the DSM-III and DSM-IIIR deﬁnitions are also
reported. Diagnosis/treatment initiation is usually made
by child psychologists/psychiatrists and, increasingly, by
paediatricians. Estimates of prevalence vary widely
depending on the study population and diagnostic crite-
ria used. For the general population, estimates based on
the HD deﬁnition are in the range of 0.5–2.4% and those
based on the ADHD deﬁnition are in the range of 5–10%.
Reports from the UK and Germany indicated that features
of the disorder arise before the age of 5 years. One source
from Germany reported that symptom recognition
occurred on average at 10.2 years of age, with 9.4% of
the sample experiencing ﬁrst symptoms at 5 years of age
or younger. European treatment guidelines have been pub-
lished and country speciﬁc treatment guidelines also exist
in the UK, Netherlands, and Germany. Pharmacotherapy
in Europe is primarily through the use of psychostimu-
lants, although these are not generally available in Italy.
CONCLUSION: The literature review established that
ADHD/HD is a recognised disorder for children in Europe.
Formal criteria are used to diagnose the disorder, studies
have measured the prevalence, demographics, age of onset
and treatment guidelines have been published.
PMH24
THERE ARE SIGNIFICANT BARRIERS TO THE
DIAGNOSIS AND TREATMENT OF ADHD IN
EUROPE
Ralston SJ1, Nuijten M2
1Eli Lilly and Company, Windlesham, Surrey, United Kingdom;
2MEDTAP International, Jisp, Netherlands
OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and costs associated
with Attention Deﬁcit/Hyperactivity Disorder (ADHD) in
children. The objective of this abstract is to present the
results on deﬁnition, gender characteristics, recognition,
delay between onset and diagnosis. METHODS: The
international literature search was complemented by
country-speciﬁc literature searches in France, Germany,
Italy, Netherlands, Spain and the UK. In each country, a
clinical expert was interviewed and reviewed the country-
speciﬁc information. RESULTS: Deﬁnition of ADHD is
not uniform across countries as the literature reﬂects 
the use of both the ICD-10 deﬁnition of Hyperkinetic 
Disorder (HD), and the DSM-IV deﬁnition of ADHD.
DSM-IV offers a broader, more encompassing deﬁnition
of ADHD when compared to HD. Reports of male to
female prevalence found conﬂicting evidence as male
cases may outnumber females by as much as 9 :1, but
other sources reported a 1 :1 ratio. ADHD/HD differ-
ences in gender is currently debated with the view that
boys exhibit more distinguishable symptoms. The litera-
ture indicated that diagnosis may be complicated by many
